Skip to main content
Caplight Logo









Algenuity

Algenuity

Private
RotterdamHealthcare & Life Scienceshttps://algenuity.com

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Algenuity operates in Healthcare & Life Sciences and is based in Rotterdam. It was founded in 2012.

Algenuity is a biotechnology company that develops, manufactures, and supplies sustainable, plant-based protein ingredients from microalgae for the food and beverage industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Sustainable Materials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Algenuity Comparables

Compare Algenuity with similar companies based on industry and business-model similarity.

Algenuity comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aliga Microalgae
91%
Allmicroalgae - Natural Products S.A.
86%
Brevel
86%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Algenuity Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for Algenuity. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Andrew Spicer

Chief Technology Officer & Founder

Founding Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 45% MoM, from 1.4K to 2K.

  • Jun 18, 2026

    Monthly visitors increased 41% MoM, reaching 1.4K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Algenuity Filings

Explore SEC and related filing metadata, where available.

Algenuity filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Algenuity's valuation, stock price, and market status.

Is Algenuity a public or private company?

Algenuity is a private company.

What is the current stock price of Algenuity?

Algenuity is a private company, so its shares have no public market price. Caplight tracks Algenuity's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Algenuity worth (valuation)?

Valuation information for Algenuity is not publicly available.

Can I buy Algenuity stock?

Algenuity shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Algenuity's last funding round?

Funding round information for Algenuity is not publicly available.

Who are the main investors in Algenuity?

Investor information for Algenuity is not publicly disclosed.

Will Algenuity IPO soon?

No public IPO plans have been announced for Algenuity.

How can I track Algenuity secondary market activity?

Caplight tracks bids, offers, and trades in Algenuity's shares on secondary markets.

Firmographic Details

HeadquartersRotterdam
Employee Range11
Year Founded2012
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?